Last reviewed 2026-04-22 · How we verify

IgPro

IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses.

IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions.

At a glance

Mechanism of action

IgPro is a polyvalent immunoglobulin preparation derived from pooled human plasma that contains a broad spectrum of antibodies against common pathogens. It functions by providing immediate passive immunity and can modulate inflammatory and autoimmune responses through multiple mechanisms including Fc receptor engagement and complement regulation. It is used in patients with primary immunodeficiencies, secondary immunodeficiencies, and certain autoimmune or inflammatory conditions.

Approved indications

• Primary immunodeficiency disorders
• Secondary immunodeficiency in hematologic malignancies
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Multifocal motor neuropathy
• Immune thrombocytopenia (ITP)

Common side effects

• Headache
• Fever
• Chills
• Fatigue
• Myalgia
• Infusion reactions
• Thrombosis (rare)

Key clinical trials

• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) (PHASE4)
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.